Peritoneal cytology of ovarian cancer patients receiving intraperitoneal therapy: Quantitation of malignant cells and response

“…Although clinical remission is often achieved after completion of the first-line treatment, 60% of patients will ultimately relapse or develop drug resistance. 8 Different treatment modalities have been used in an attempt to overcome these limits, such as secondary cytoreduction, second-line chemotherapeutic drugs, cytoreductive surgery (CRS) plus hypertermic intraperitoneal chemotherapy (HIPEC), radiotherapy, immunotherapy and hormone therapy. 9 To date, with the exception of CRS plus HIPEC, none of the aforementioned approaches has been found to have a significant impact on survival.…”

Section: Introductionmentioning

confidence: 99%

DNA ploidy and S-phase fraction analysis in peritoneal carcinomatosis from ovarian cancer: correlation with clinical pathological factors and response to chemotherapy

Carloni¹,

Gallerani²,

Tesei³

et al. 2017

OTT

View full text Add to dashboard Cite

ObjectiveWe investigated the correlation between ploidy or S-phase fraction (SPF) and the clinical pathological characteristics of patients with peritoneal carcinomatosis from ovarian cancer. We also assessed their relation with the in vivo and in vitro response to several chemotherapeutic agents.Patients and methodsFifty-three patients with peritoneal carcinomatosis from ovarian cancer were enrolled. Frozen tumor tissue was dissociated by a detergent–trypsin method, and the resulting cell suspension was stained with RNase A and propidium iodide. Samples were then analyzed for ploidy and SPF by flow cytometry. Fresh tumor tissue was dissociated by enzymatic digestion, and cells were exposed to different concentrations of cisplatin, adriamycin, carboplatin, gemcitabine and taxol for 72 hours. In vitro drug sensitivity was then measured using the sulforhodamine B assay.ResultsNo significant correlation was found between ploidy or SPF and patient characteristics, even though primary carcinomas were mainly hyperdiploid and more proliferative than recurrent tumors. SPF differed significantly among ploidy categories (P=0.01), and high SPF was associated with short-term survival (P=0.48). Patients with multiploid tumors were the most resistant to platinum-based chemotherapy, whereas those with hyperdiploid tumors were the most responsive. In vitro multiploid tumors were the least sensitive, while hypodiploid samples showed the highest sensitivity to the tested drugs. Sensitivity to adriamycin was significantly correlated with ploidy (P=0.03), whereas sensitivity to taxol was correlated with SPF (P=0.04).ConclusionOur results indicate that ploidy and SPF could facilitate the choice of therapy for patients with peritoneal carcinomatosis.

show abstract

Les Critères Cytologiques Des Épanchements Après Irradiation Et/Ou Chimiothérapie

Klijanienko

2005

Revue Francophone des Laboratoires

View full text Add to dashboard Cite

Peritoneal cytology of ovarian cancer patients receiving intraperitoneal therapy: Quantitation of malignant cells and response

Cited by 4 publications

References 0 publications

The treatment of microscopic residual ovarian cancer with intraperitoneal interferon: a clinical and flow cytometric study

The treatment of microscopic residual ovarian cancer with intraperitoneal interferon: a clinical and flow cytometric study

DNA ploidy and S-phase fraction analysis in peritoneal carcinomatosis from ovarian cancer: correlation with clinical pathological factors and response to chemotherapy

Les Critères Cytologiques Des Épanchements Après Irradiation Et/Ou Chimiothérapie

Contact Info

Product

Resources

About